July 28, 2025
Devens, MA, USA — Veranova, a global leader in the development and manufacturing of specialty and complex active pharmaceutical ingredients (API) for the pharmaceutical and biotech sectors, is pleased to announce the appointment of Thomas Rohrer as Vice President of Bioconjugation. This appointment follows a recently announced investment to establish cGMP bioconjugation capabilities at its Devens, MA site.

Thomas brings over 40 years of experience and a comprehensive understanding of biological process development and clinical manufacturing, including 30 years of licensed biological manufacturing. Throughout his career, he has successfully delivered complex biological programs for both clinical and commercial applications, including mammalian, microbial, vaccine, and gene therapy drug substances.

He spent 16 years at Lonza, where he led teams across several locations and departments, including Biopharmaceutical Manufacturing, Antibody Drug Conjugation, Biochemical Technologies, Project Evaluation and Commercial Development. His extensive industry experience also includes Director of Process Development at Human Genome Sciences (later acquired by GSK), Otsuka America Pharmaceutical, Guidepoint Global LLC, Gentz Biopharmaceutical Consulting LLC, and most recently as Senior Director of Bioconjugate Technology Support at Samsung Biologics.  

Thomas holds a Bachelor of Science in Biochemistry from Shepherd University and pursued further studies at the University of Maryland’s Graduate School of Engineering in the Department of Chemical and Biochemical Engineering, and the National Institute for Public Health and the Environment in the Netherlands (Rijkes Institute voor de Volksgezondheid). He has authored multiple publications and presentations on the manufacturing of Antibody Drug Conjugates and bioprocesses used for the manufacturing of biological therapeutics.

“We are delighted to welcome Tom as our Vice President of Bioconjugation,” said Rohtash Kumar, Senior Vice President of Development Operations and Chief Technology Officer at Veranova. “His invaluable experience and thought leadership in biological manufacturing will be critical as we continue to build and grow our bioconjugation offering in Devens, providing a more comprehensive suite of services to partners developing Antibody Drug Conjugates and other bioconjugates.”
About Veranova

Veranova is a global leader in process development and manufacturing of APIs, with a focus on specialty and complex chemistry for small molecules, antibody-drug conjugates, oligonucleotides and peptides. Veranova is headquartered in Devens, Massachusetts and has operations in North America and Europe.